Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 16;16(20):12955-12976.
doi: 10.18632/aging.206135. Epub 2024 Oct 16.

Longevity biotechnology: bridging AI, biomarkers, geroscience and clinical applications for healthy longevity

Yu-Xuan Lyu  1   2 Qiang Fu  3   4   5 Dominika Wilczok  6   7 Kejun Ying  8 Aaron King  9 Adam Antebi  2   10 Aleksandar Vojta  11 Alexandra Stolzing  12 Alexey Moskalev  13 Anastasia Georgievskaya  14 Andrea B Maier  15 Andrea Olsen  16 Anja Groth  17 Anna Katharina Simon  18   19 Anne Brunet  20 Aisyah Jamil  21 Anton Kulaga  22   23 Asif Bhatti  24 Benjamin Yaden  25 Bente Klarlund Pedersen  26 Björn Schumacher  27 Boris Djordjevic  28   29 Brian Kennedy  15 Chieh Chen  30   31 Christine Yuan Huang  32 Christoph U Correll  33   34 Coleen T Murphy  35   36 Collin Y Ewald  37 Danica Chen  38   39   40 Dario Riccardo Valenzano  41 Dariusz Sołdacki  42 David Erritzoe  43 David Meyer  27 David A Sinclair  44 Eduardo Nunes Chini  45 Emma C Teeling  46 Eric Morgen  47 Eric Verdin  48 Erik Vernet  49 Estefano Pinilla  50 Evandro F Fang  51 Evelyne Bischof  52 Evi M Mercken  53 Fabian Finger  54 Folkert Kuipers  55 Frank W Pun  56 Gabor Gyülveszi  57 Gabriele Civiletto  58 Garri Zmudze  59 Gil Blander  60 Harold A Pincus  61 Joshua McClure  62 James L Kirkland  63 James Peyer  64 Jamie N Justice  65 Jan Vijg  66 Jennifer R Gruhn  67 Jerry McLaughlin  68 Joan Mannick  69 João Passos  70 Joseph A Baur  71 Joe Betts-LaCroix  72 John M Sedivy  73 John R Speakman  74 Jordan Shlain  75 Julia von Maltzahn  76 Katrin I Andreasson  77 Kelsey Moody  78 Konstantinos Palikaras  79 Kristen Fortney  47 Laura J Niedernhofer  80 Lene Juel Rasmussen  81 Liesbeth M Veenhoff  55 Lisa Melton  82 Luigi Ferrucci  83 Marco Quarta  84   85   86 Maria Koval  87 Maria Marinova  88 Mark Hamalainen  89 Maximilian Unfried  15   90 Michael S Ringel  91 Milos Filipovic  92 Mourad Topors  93 Natalia Mitin  94 Nawal Roy  95 Nika Pintar  96 Nir Barzilai  97 Paolo Binetti  50 Parminder Singh  48 Paul Kohlhaas  98 Paul D Robbins  99 Paul Rubin  47 Peter O Fedichev  100 Petrina Kamya  101 Pura Muñoz-Canoves  102 Rafael de Cabo  103 Richard G A Faragher  104 Rob Konrad  105 Roberto Ripa  2 Robin Mansukhani  106 Sabrina Büttner  107 Sara A Wickström  108 Sebastian Brunemeier  109 Sergey Jakimov  59 Shan Luo  110 Sharon Rosenzweig-Lipson  68 Shih-Yin Tsai  111 Stefanie Dimmeler  112 Thomas A Rando  113 Tim R Peterson  114 Tina Woods  115   116 Tony Wyss-Coray  77 Toren Finkel  117 Tzipora Strauss  118   119 Vadim N Gladyshev  8 Valter D Longo  120 Varun B Dwaraka  121 Vera Gorbunova  122 Victoria A Acosta-Rodríguez  123 Vincenzo Sorrentino  15 Vittorio Sebastiano  124 Wenbin Li  125 Yousin Suh  126 Alex Zhavoronkov  21 Morten Scheibye-Knudsen  81 Daniela Bakula  81
Affiliations
Review

Longevity biotechnology: bridging AI, biomarkers, geroscience and clinical applications for healthy longevity

Yu-Xuan Lyu et al. Aging (Albany NY). .

Abstract

The recent unprecedented progress in ageing research and drug discovery brings together fundamental research and clinical applications to advance the goal of promoting healthy longevity in the human population. We, from the gathering at the Aging Research and Drug Discovery Meeting in 2023, summarised the latest developments in healthspan biotechnology, with a particular emphasis on artificial intelligence (AI), biomarkers and clocks, geroscience, and clinical trials and interventions for healthy longevity. Moreover, we provide an overview of academic research and the biotech industry focused on targeting ageing as the root of age-related diseases to combat multimorbidity and extend healthspan. We propose that the integration of generative AI, cutting-edge biological technology, and longevity medicine is essential for extending the productive and healthy human lifespan.

Keywords: artificial intelligence; biotechnology; healthy longevity.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST: A.G. is affiliated with Haut.AI. A.K.S. is consulting for The Longevity Lab and Primeadine. D.S. is an employee of the Longevity Center Group. J.L.K. has a financial interest related to this research, including patents and pending patents covering senolytic drugs and their uses that are held by Mayo Clinic. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic conflict of interest policies. G.B. is an InsideTracker employee, and InsideTracker is the sole funder of Dr. Blander. G.C is the employee of DSM-Firmenich (Kaiseraugst, Switzerland). J.H. is a founder and scientific advisory board member of LongLifeRx and Aiance. J.S. is affiliated with Private Medical. J.V. is a co-founder of Singulomics Inc. and Mutagentech Inc. K.J.M. holds equity in Lysoclear, Inc. which is commercializing the presented technology. K.P. is funded by the Fondation Santé (19656) and the European Union (European Research Council; ERC), under grant agreement “ERC-GA101077374-SynaptoMitophagy”. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Research Council. Neither the European Union nor the granting authority can be held responsible for them. M.H. is affiliated with Synthego, Frontier Bio, Ligandal, Longshot Space. M.S-K. is supported by the Novo Nordisk Foundation Challenge Programme (NNF17OC0027812), the Nordea Foundation (02-2017-1749), the Neye Foundation, the Lundbeck Foundation (R324-2019-1492), the Ministry of Higher Education and Science (0238-00003B), VitaDAO and Insilico Medicine. M.Q. is founder and shareholder of Rubedo Life Sciences and Turn Biotechnologies. P.K., F.W.P., A.J. and A.Z. are employed at Insilico Medicine. P.M. was employed at Pompeu Fabra University and currently is employed at Altos Labs. T.F. co-founder and equity holder Generian Pharmaceuticals and Coloma Therapeutics.

Figures

Figure 1
Figure 1
Timeline of longevity biotechnology. Key breakthroughs the AI, Biomarkers and clocks, Geroscience, and Clinical trials and applications in ageing and longevity fields since 2013.
Figure 2
Figure 2
Framework of personalized, data-driven longevity medicine.
Figure 3
Figure 3
Integration of AI, biomarkers and clocks, geroscience, and longevity medicine in advancing human healthspan.

References

    1. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell. 2023; 186:243–78. 10.1016/j.cell.2022.11.001 - DOI - PubMed
    1. Campisi J, Kapahi P, Lithgow GJ, Melov S, Newman JC, Verdin E. From discoveries in ageing research to therapeutics for healthy ageing. Nature. 2019; 571:183–92. 10.1038/s41586-019-1365-2 - DOI - PMC - PubMed
    1. Zhavoronkov A, Mamoshina P. Deep Aging Clocks: The Emergence of AI-Based Biomarkers of Aging and Longevity. Trends Pharmacol Sci. 2019; 40:546–9. 10.1016/j.tips.2019.05.004 - DOI - PubMed
    1. Moqri M, Herzog C, Poganik JR, Ying K, Justice JN, Belsky DW, Higgins-Chen AT, Chen BH, Cohen AA, Fuellen G, Hägg S, Marioni RE, Widschwendter M, et al.. Validation of biomarkers of aging. Nat Med. 2024; 30:360–72. 10.1038/s41591-023-02784-9 - DOI - PMC - PubMed
    1. Bao H, Cao J, Chen M, Chen M, Chen W, Chen X, Chen Y, Chen Y, Chen Y, Chen Z, Chhetri JK, Ding Y, Feng J, et al., and Aging Biomarker Consortium. Biomarkers of aging. Sci China Life Sci. 2023; 66:893–1066. 10.1007/s11427-023-2305-0 - DOI - PMC - PubMed

LinkOut - more resources